CRIS
Revolutionizing Cancer Treatment: Curis' Q4 2025 Update Marks a New Era in Lymphoma and Leukemia Therapies
Curis, a biotechnology company dedicated to delivering innovative cancer treatments, has made significant strides in its mission to improve the lives of patients with lymphoma and leukemia. In their recent Q4 2025 business update call, Curis' leadership highlighted promising developments across multiple clinical studies. The Take Aim Lymphoma study,